Efficacy and Safety of Ivabradine Once-Daily Prolonged-Release versus Twice-Daily Immediate-Release Formulation in Patients with Stable Chronic Heart Failure with Systolic Dysfunction: A Randomized, Double-Blind, Phase 3 Non-Inferiority (PROFICIENT) Study

INTRODUCTION: Dosing frequency is an important factor influencing medication compliance in patients with heart failure (HF), which in turn is imperative in achieving the desired therapeutic outcome. Here we assessed the efficacy and safety of ivabradine prolonged-release (PR) once-daily (test) vs. i...

Descripción completa

Detalles Bibliográficos
Autor principal: Mullasari, Ajit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584698/
https://www.ncbi.nlm.nih.gov/pubmed/33006062
http://dx.doi.org/10.1007/s40119-020-00200-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584698/
https://www.ncbi.nlm.nih.gov/pubmed/33006062
http://dx.doi.org/10.1007/s40119-020-00200-8

Ejemplares similares